{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:56Z","timestamp":1707525176901},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,28]]},"DOI":"10.7759\/cureus.41105","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T22:05:21Z","timestamp":1687989921000},"source":"Crossref","is-referenced-by-count":0,"title":["Cytotoxic Lesions of the Corpus Callosum (CLOCC) Suggesting Exacerbation by Heterogeneous COVID-19 Booster Vaccination"],"prefix":"10.7759","author":[{"given":"Yuta","family":"Chiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1440","article-title":"Reversible lesion in the splenium of the corpus callosum","volume":"9","author":"Tetsuka S","year":"2019","unstructured":"Tetsuka S. Reversible lesion in the splenium of the corpus callosum. Brain Behav. 2019, 9:e01440. 10.1002\/brb3.1440","journal-title":"Brain Behav"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10611-9","article-title":"COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2","volume":"268","author":"Sriwastava S","year":"2021","unstructured":"Sriwastava S, Tandon M, Podury S, et al.. COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2. J Neurol. 2021, 268:4448-78. 10.1007\/s00415-021-10611-9","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e228","article-title":"Cytotoxic lesion of the corpus callosum (CLOCCs) after SARS-CoV-2 mRNA vaccination","volume":"36","author":"Youn T","year":"2021","unstructured":"Youn T, Yang H. Cytotoxic lesion of the corpus callosum (CLOCCs) after SARS-CoV-2 mRNA vaccination. J Korean Med Sci. 2021, 36:e228. 10.3346\/jkms.2021.36.e228","journal-title":"J Korean Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/19714009221096825","article-title":"Reversible cytotoxic lesion of the corpus callosum following SARS-CoV-2 mRNA vaccine administration: a finding to be aware of","volume":"35","author":"Procaccini L","year":"2022","unstructured":"Procaccini L, Mincuzzi E, Bernardini A, Franchi P, Voicu IP, Caulo M. Reversible cytotoxic lesion of the corpus callosum following SARS-CoV-2 mRNA vaccine administration: a finding to be aware of. Neuroradiol J. 2022, 35:758-62. 10.1177\/19714009221096825","journal-title":"Neuroradiol J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-022-03010-y","article-title":"Cytotoxic lesions of the corpus callosum after COVID-19 vaccination","volume":"64","author":"Ohara H","year":"2022","unstructured":"Ohara H, Shimizu H, Kasamatsu T, et al.. Cytotoxic lesions of the corpus callosum after COVID-19 vaccination. Neuroradiology. 2022, 64:2085-9. 10.1007\/s00234-022-03010-y","journal-title":"Neuroradiology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26339","article-title":"Neurological events reported after COVID-19 vaccines: an analysis of VAERS","volume":"91","author":"Frontera JA","year":"2022","unstructured":"Frontera JA, Tamborska AA, Doheim MF, et al.. Neurological events reported after COVID-19 vaccines: an analysis of VAERS. Ann Neurol. 2022, 91:756-71. 10.1002\/ana.26339","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05662-9","article-title":"Spectrum of neurological complications following COVID-19 vaccination","volume":"43","author":"Garg RK","year":"2022","unstructured":"Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022, 43:3-40. 10.1007\/s10072-021-05662-9","journal-title":"Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12030407","article-title":"COVID-19 vaccination and neurological manifestations: a review of case reports and case series","volume":"12","author":"Sriwastava S","year":"2022","unstructured":"Sriwastava S, Sharma K, Khalid SH, et al.. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022, 12:10.3390\/brainsci12030407","journal-title":"Brain Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin U","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, et al.. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020, 586:594-9. 10.1038\/s41586-020-2814-7","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination","volume":"600","author":"Pozzetto B","year":"2021","unstructured":"Pozzetto B, Legros V, Djebali S, et al.. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021, 600:701-6. 10.1038\/s41586-021-04120-y","journal-title":"Nature"},{"key":"ref11","unstructured":"Interim report after the third dose for first-time mRNA vaccine recipients (9). https.\/\/www.mhlw.go.jp\/content\/10601000\/001011553.pdf.."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9272074","article-title":"The spectrum of acute disseminated encephalomyelitis and mild encephalopathy with reversible splenial lesion","volume":"2019","author":"S\u00e1enz-Farret M","year":"2019","unstructured":"S\u00e1enz-Farret M, Cansino-Torres MA, Sandoval-Rodr\u00edguez V, Navarro-Ibarra R, Z\u00fa\u00f1iga-Ram\u00edrez C. The spectrum of acute disseminated encephalomyelitis and mild encephalopathy with reversible splenial lesion. Case Rep Neurol Med. 2019, 2019:9272074. 10.1155\/2019\/9272074","journal-title":"Case Rep Neurol Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.12.019","article-title":"Clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination","volume":"349","author":"Takanashi J","year":"2015","unstructured":"Takanashi J, Shiihara T, Hasegawa T, Takayanagi M, Hara M, Okumura A, Mizuguchi M. Clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination. J Neurol Sci. 2015, 349:226-8. 10.1016\/j.jns.2014.12.019","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2017160085","article-title":"Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations","volume":"37","author":"Starkey J","year":"2017","unstructured":"Starkey J, Kobayashi N, Numaguchi Y, Moritani T. Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations. Radiographics. 2017, 37:562-76. 10.1148\/rg.2017160085","journal-title":"Radiographics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106839","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination","volume":"208","author":"Vogrig A","year":"2021","unstructured":"Vogrig A, Janes F, Gigli GL, et al.. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg. 2021, 208:106839. 10.1016\/j.clineuro.2021.106839","journal-title":"Clin Neurol Neurosurg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2021.0869","article-title":"Preliminary analysis of association between COVID-19 vaccination and sudden hearing loss using US centers for disease control and prevention vaccine adverse events reporting system data","volume":"147","author":"Formeister EJ","year":"2021","unstructured":"Formeister EJ, Chien W, Agrawal Y, Carey JP, Stewart CM, Sun DQ. Preliminary analysis of association between COVID-19 vaccination and sudden hearing loss using US centers for disease control and prevention vaccine adverse events reporting system data. JAMA Otolaryngol Head Neck Surg. 2021, 147:674-6. 10.1001\/jamaoto.2021.0869","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003275","article-title":"Otologic manifestations after COVID-19 vaccination: the house ear clinic experience","volume":"42","author":"Wichova H","year":"2021","unstructured":"Wichova H, Miller ME, Derebery MJ. Otologic manifestations after COVID-19 vaccination: the house ear clinic experience. Otol Neurotol. 2021, 42:e1213-8. 10.1097\/MAO.0000000000003275","journal-title":"Otol Neurotol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12030306","article-title":"Autoimmune vestibulopathy - a case series","volume":"12","author":"Mendis S","year":"2022","unstructured":"Mendis S, Longley N, Morley S, Korres G, Kaski D. Autoimmune vestibulopathy - a case series. Brain Sci. 2022, 12:10.3390\/brainsci12030306","journal-title":"Brain Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17435","article-title":"Sudden sensorineural hearing loss following the second dose of COVID-19 vaccine","volume":"13","author":"Tsetsos N","year":"2021","unstructured":"Tsetsos N, Poutoglidis A, Vlachtsis K, Kilmpasanis A, Gougousis S. Sudden sensorineural hearing loss following the second dose of COVID-19 vaccine. Cureus. 2021, 13:e17435. 10.7759\/cureus.17435","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson CR","year":"2021","unstructured":"Simpson CR, Shi T, Vasileiou E, et al.. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021, 27:1290-7. 10.1038\/s41591-021-01408-4","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/165513-cytotoxic-lesions-of-the-corpus-callosum-clocc-suggesting-exacerbation-by-heterogeneous-covid-19-booster-vaccination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:44Z","timestamp":1707509144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/165513-cytotoxic-lesions-of-the-corpus-callosum-clocc-suggesting-exacerbation-by-heterogeneous-covid-19-booster-vaccination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.41105","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}